Ultragenyx Pharmaceutical's market cap is currently $3.92B. The company's EPS TTM is $-6.337; its P/E ratio is ―; Ultragenyx Pharmaceutical is scheduled to report earnings on February 13, 2025, and the estimated EPS forecast is $-1.47. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 434.25M	$ 363.33M	$ 351.41M	$ 271.03M	$ 103.71M
Gross Profit	$ 389.04M	$ 335.01M	$ 335.40M	$ 264.90M	$ 94.71M
Operating Income	$ -569.21M	$ -648.92M	$ -381.74M	$ -330.12M	$ -424.17M
EBITDA	$ -516.45M	$ -640.51M	$ -410.32M	$ -139.81M	$ -389.77M
Net Income	$ -606.64M	$ -707.42M	$ -454.02M	$ -186.57M	$ -402.73M
Balance Sheet
Cash & Short-Term Investments	$ 577.21M	$ 896.73M	$ 999.13M	$ 1.21B	$ 760.40M
Total Assets	$ 1.49B	$ 1.55B	$ 1.52B	$ 1.76B	$ 1.14B
Total Debt	$ 43.17M	$ 31.59M	$ 41.97M	$ 48.23M	$ 36.99M
Net Debt	$ -170.41M	$ -101.35M	$ -265.61M	$ -665.30M	$ -396.59M
Total Liabilities	$ 1.22B	$ 1.19B	$ 599.84M	$ 605.18M	$ 481.73M
Stockholders' Equity	$ 275.41M	$ 352.49M	$ 922.56M	$ 1.15B	$ 653.76M
Cash Flow
Free Cash Flow	$ -521.57M	$ -526.59M	$ -411.79M	$ -176.13M	$ -370.21M
Operating Cash Flow	$ -474.81M	$ -380.46M	$ -338.69M	$ -132.22M	$ -345.38M
Investing Cash Flow	$ 168.00M	$ -291.65M	$ -195.37M	$ -179.12M	$ -13.04M
Financing Cash Flow	$ 388.14M	$ 501.21M	$ 118.55M	$ 600.27M	$ 679.31M

Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Income Statement >

Ultragenyx Pharmaceutical Debt to Assets

Balance Sheet >

Ultragenyx Pharmaceutical Cash Flow

Cash Flow >

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing